Literature DB >> 8757689

Amphotericin B: an update.

K M Abu-Salah1.   

Abstract

Amphotericin B is the most important clinically and best defined chemically of the macrolide heptaene antibiotics. A fermentation product of the soil actinomycetes Streptomyces nodosus, amphotericin B binds selectively to ergosterol in the cell membrane of susceptible fungi, inducing changes in permeability that can produce lethal cell injury. Available since 1960, amphotericin B remains the treatment of choice for most serious systemic fungal infections. This review highlights some important aspects of the physicochemical properties of amphotericin B and their utilisation in its quantitative determination in biological fluids. Its mechanism of action is re-appraised in the light of recent results with regard to its effects on the physical and functional properties of synthetic and natural membranes. Attempts to reduce its toxic effects to host cells and to improve its therapeutic index are evaluated. In addition, the therapeutic values of amphotericin B, apart from its antibiotic activity, are discussed.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8757689

Source DB:  PubMed          Journal:  Br J Biomed Sci        ISSN: 0967-4845            Impact factor:   3.829


  13 in total

Review 1.  Liposomal amphotericin B. Therapeutic use in the management of fungal infections and visceral leishmaniasis.

Authors:  A J Coukell; R N Brogden
Journal:  Drugs       Date:  1998-04       Impact factor: 9.546

2.  Complete genome sequence of Streptomyces sp. HSG2 from rhizosphere soil of mangrove in Qingmei Gang, Sanya.

Authors:  Shengxiang Pei; Siwen Niu; Fuquan Xie; Shuang Zhang; Wenjing Wang; Gaiyun Zhang
Journal:  Arch Microbiol       Date:  2021-05-01       Impact factor: 2.552

3.  Differential expression of cytokines and chemokines in human monocytes induced by lipid formulations of amphotericin B.

Authors:  M Simitsopoulou; E Roilides; J Dotis; M Dalakiouridou; F Dudkova; E Andreadou; T J Walsh
Journal:  Antimicrob Agents Chemother       Date:  2005-04       Impact factor: 5.191

4.  Bluemomycin, a new naphthoquinone derivative from Streptomyces sp. with antimicrobial and cytotoxic properties.

Authors:  C Balachandran; N A Al-Dhabi; V Duraipandiyan; S Ignacimuthu
Journal:  Biotechnol Lett       Date:  2021-01-29       Impact factor: 2.461

5.  Enzymatic Biosynthesis of Novel Resveratrol Glucoside and Glycoside Derivatives.

Authors:  Ramesh Prasad Pandey; Prakash Parajuli; Ju Yong Shin; Jisun Lee; Seul Lee; Young-Soo Hong; Yong Il Park; Joong Su Kim; Jae Kyung Sohng
Journal:  Appl Environ Microbiol       Date:  2014-09-19       Impact factor: 4.792

6.  New insight into amphotericin B resistance in Aspergillus terreus.

Authors:  Gerhard Blum; Caroline Hörtnagl; Emina Jukic; Thomas Erbeznik; Thomas Pümpel; Hermann Dietrich; Markus Nagl; Cornelia Speth; Günter Rambach; Cornelia Lass-Flörl
Journal:  Antimicrob Agents Chemother       Date:  2013-01-14       Impact factor: 5.191

7.  Salvage treatment with amphotericin B in progressive human alveolar echinococcosis.

Authors:  Stefan Reuter; Andreas Buck; Olaf Grebe; Karin Nüssle-Kügele; Peter Kern; Burkhard J Manfras
Journal:  Antimicrob Agents Chemother       Date:  2003-11       Impact factor: 5.191

8.  Effect of amphotericin B on larval growth of Echinococcus multilocularis.

Authors:  Stefan Reuter; Marion Merkle; Klaus Brehm; Peter Kern; Burkhard Manfras
Journal:  Antimicrob Agents Chemother       Date:  2003-02       Impact factor: 5.191

Review 9.  Amphotericin-B colloidal dispersion. A review of its use against systemic fungal infections and visceral leishmaniasis.

Authors:  R N Brogden; K L Goa; A J Coukell
Journal:  Drugs       Date:  1998-09       Impact factor: 9.546

10.  Engineered biosynthesis of disaccharide-modified polyene macrolides.

Authors:  Eimear De Poire; Niamh Stephens; Bernard Rawlings; Patrick Caffrey
Journal:  Appl Environ Microbiol       Date:  2013-08-02       Impact factor: 4.792

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.